GEAP201813826A - Bremelanotide therapy for female sexual dysfunction - Google Patents

Bremelanotide therapy for female sexual dysfunction

Info

Publication number
GEAP201813826A
GEAP201813826A GEAP201813826A GEAP2018013826A GEAP201813826A GE AP201813826 A GEAP201813826 A GE AP201813826A GE AP201813826 A GEAP201813826 A GE AP201813826A GE AP2018013826 A GEAP2018013826 A GE AP2018013826A GE AP201813826 A GEAP201813826 A GE AP201813826A
Authority
GE
Georgia
Prior art keywords
bremelanotide
therapy
sexual dysfunction
female sexual
female
Prior art date
Application number
GEAP201813826A
Other languages
English (en)
Georgian (ka)
Inventor
Jeffrey D Edelson
Robert Jordan
Carl Spana
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEAP201813826(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of GEAP201813826A publication Critical patent/GEAP201813826A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
GEAP201813826A 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction GEAP201813826A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28

Publications (1)

Publication Number Publication Date
GEAP201813826A true GEAP201813826A (en) 2018-10-25

Family

ID=50628268

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201813826A GEAP201813826A (en) 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction
GEAP201313826A GEP20196947B (en) 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201313826A GEP20196947B (en) 2012-11-05 2013-11-05 Bremelanotide therapy for female sexual dysfunction

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN104755094A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (2) GEAP201813826A (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915B1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60112440T2 (de) * 2000-05-31 2006-04-20 Novo Nordisk A/S Wegwerfbare zweispitzige injektionsnadel
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7758548B2 (en) * 2004-12-09 2010-07-20 West Pharmaceutical Services Of Delaware, Inc. Coupling for an auto-injection device
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
EP2300036B1 (en) * 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
KR102071212B1 (ko) * 2010-04-21 2020-01-30 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스

Also Published As

Publication number Publication date
HK1211227A1 (en) 2016-05-20
CA2890081A1 (en) 2014-05-08
PL2916856T3 (pl) 2019-02-28
ES2701444T3 (es) 2019-02-22
MY179755A (en) 2020-11-12
CN104755094A (zh) 2015-07-01
US20150231196A1 (en) 2015-08-20
US20220362328A1 (en) 2022-11-17
US20190216888A1 (en) 2019-07-18
ES2701444T5 (es) 2024-05-21
UA118656C2 (uk) 2019-02-25
JP2016503406A (ja) 2016-02-04
GEP20196947B (en) 2019-02-11
DK2916856T4 (da) 2024-01-22
US20210060120A1 (en) 2021-03-04
AU2013337341B2 (en) 2018-02-22
EA032959B1 (ru) 2019-08-30
ZA201503128B (en) 2016-11-30
EA032959B9 (ru) 2019-11-27
SG11201502949QA (en) 2015-06-29
EP2916856B1 (en) 2018-09-19
WO2014071339A3 (en) 2014-06-12
US20180085425A1 (en) 2018-03-29
US9700592B2 (en) 2017-07-11
US9352013B2 (en) 2016-05-31
MX362610B (es) 2019-01-28
EP2916856A4 (en) 2016-06-22
PH12015500915A1 (en) 2015-06-29
US20240335502A1 (en) 2024-10-10
FI2916856T4 (fi) 2024-01-15
BR112015009936A8 (pt) 2019-09-17
CN117860866A (zh) 2024-04-12
IL238276A0 (en) 2015-06-30
BR112015009936A2 (pt) 2017-07-11
US20140378392A1 (en) 2014-12-25
US10286034B2 (en) 2019-05-14
KR102253526B1 (ko) 2021-05-18
PL2916856T5 (pl) 2024-01-29
AU2013337341A1 (en) 2015-05-07
NZ707246A (en) 2019-03-29
EA201590760A1 (ru) 2015-10-30
IL238276B (en) 2020-04-30
WO2014071339A2 (en) 2014-05-08
PH12015500915B1 (en) 2015-06-29
EP2916856A2 (en) 2015-09-16
MX2015005486A (es) 2015-11-13
EP2916856B2 (en) 2023-10-18
KR20150081345A (ko) 2015-07-13
JP6567971B2 (ja) 2019-08-28
DK2916856T3 (en) 2019-01-14

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
PL2964315T3 (pl) Układ do leczenia dysfunkcji neuromotorycznej
IL241101A0 (en) Medicinal uses of empagliflozin
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
IL241102A0 (en) Medicinal uses of empagliflozin
GB201321729D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321732D0 (en) Therapeutic agents
SI2981271T1 (sl) Terapevtske uporabe empagliflozina
IL245524A0 (en) New methods for the production of active tert
GB201321737D0 (en) Therapeutic Agents
EP3065690A4 (en) Sexual stimulation devices
EP2777680A4 (en) DEVICE FOR FEMALE SEXUAL STIMULATION
GB201321735D0 (en) Therapeutic Agents
IN2013DE00266A (enExample)
GB201321731D0 (en) Therapeutic agents
EP2777679A4 (en) DEVICE FOR MALE SEXUAL STIMULATION
ZA201503128B (en) Bremelanotide therapy for female sexual dysfunction
TWM475278U (en) Structure of sexual vibrator
TWD158466S (zh) 電位治療器
ES1074026Y (es) Dispositivo estimulador del aparato genital masculino y femenino.